New hope for tough pancreatic cancer: personalized drug cocktail enters trials

NCT ID NCT06483555

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a low dose of erlotinib to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective for people with advanced pancreatic cancer. Participants are grouped by tumor type: those with 'basal-like' tumors get the new combo, while those with 'classical' tumors receive standard care. The trial aims to improve survival and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine, nab-paclitaxel, and erlotinib
What this could lead to: If successful, this could lead to a more effective treatment for people with a specific type of pancreatic cancer (basal-like) that is often harder to treat.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so results may not apply to everyone. Adding erlotinib may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell neoplasm malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BASAL CELL NEOPLASM METASTATIC PANCREATIC CANCER PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.